PSNL Stock Analysis: Personalis | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 1.534m USD | 12M Return: 103.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.2M
Qual. Beats: 0
Rev. Trend: -5.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Personalis, Inc. (NASDAQ: PSNL) is a U.S.-based, small-cap life sciences tools and services company that develops and commercializes advanced cancer genomic tests and services for customers in the United States and internationally. The company was incorporated in 2011, is headquartered in Fremont, California, and went public in June 2019.
The companys core offerings center on tumor-informed liquid biopsy tests (such as NeXT Personal and NeXT Personal Dx) for minimal residual disease (MRD) detection and therapy monitoring, as well as tissue-based solutions like ImmunoID NeXT and NeXT Dx that combine whole exome and whole transcriptome sequencing to support tumor profiling and therapy selection. Personalis also performs whole exome sequencing of matched cancer tissue/blood samples for diagnostic firms and whole genome sequencing for large-scale research initiatives such as population sequencing programs.
Personalis operates a hybrid business model spanning clinical diagnostics and research services, serving pharmaceutical and biopharmaceutical companies, diagnostics firms, universities, non-profits, government entities, and cancer patients. Its tests are used by physicians for residual/recurrence detection and therapy monitoring, and by drug developers for translational research, biomarker discovery, and clinical trial support. The company has a strategic collaboration with Tempus AI aimed at expanding testing access to colorectal cancer patients, an area of growing focus within the precision oncology and companion diagnostics market.
- NeXT Personal MRD adoption accelerates liquid biopsy revenue growth
- Medicare reimbursement coverage decision remains key catalyst
- Capital raise risk persists as cash burn continues
| Net Income: -95.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA -8.92 > 1.0 |
| NWC/Revenue: 339.7% < 20% (prev 206.0%; Δ 133.7% < -1%) |
| CFO/TA -0.24 > 3% & CFO -79.5m > Net Income -95.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.2m) vs 12m ago 19.13% < -2% |
| Gross Margin: 13.72% > 18% (prev 33.30%; Δ -19.59% > 0.5%) |
| Asset Turnover: 21.55% > 50% (prev 31.35%; Δ -9.80% > 0%) |
| Interest Coverage Ratio: -425.7 > 6 (EBIT TTM -95.4m / Interest Expense TTM 224k) |
| A: 0.67 (Total Current Assets 258.2m - Total Current Liabilities 39.0m) / Total Assets 325.4m |
| B: -2.03 (Retained Earnings -661.3m / Total Assets 325.4m) |
| C: -0.32 (EBIT TTM -95.4m / Avg Total Assets 299.4m) |
| D: 3.61 (Book Value of Equity 254.8m / Total Liabilities 70.6m) |
| Altman-Z'' = -0.56 = B |
| DSRI: 1.58 (Receivables 13.0m/11.0m, Revenue 64.5m/85.7m) |
| GMI: 2.43 (GM 33.30% / 13.72%) |
| AQI: 1.12 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.75 (Revenue 64.5m / 85.7m) |
| TATA: -0.05 (NI -95.6m - CFO -79.5m) / TA 325.4m) |
| Beneish M = -1.37 (Cap -4..+1) = D |
As of July 11, 2026, the stock is trading at USD 14.07 with a total of 3,769,195 shares traded. Over the past week, the price has changed by +3.30%, over one month by +46.41%, over three months by +133.72% and over the past year by +103.32%.
Current recommended Stop Loss: 12.80 (which is 9% or 1.2 ATR below the current price).
Personalis has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy PSNL.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.4 | -18.8% |
P/S = 23.78
P/B = 5.7999
Revenue TTM = 64.5m USD
EBIT TTM = -95.4m USD
EBITDA TTM = -85.5m USD
Long Term Debt = 31.0m USD (estimated: total debt 38.8m - short term 7.76m)
Short Term Debt = 7.76m USD (from shortTermDebt, last quarter)
Debt = 38.8m USD (from shortLongTermDebtTotal, last quarter) (leases 37.9m already included)
Net Debt = -194.4m USD (calculated: Debt 38.8m - CCE 233.2m)
Enterprise Value = 1.34b USD (1.53b + Debt 38.8m - CCE 233.2m)
Interest Coverage Ratio = -425.7 (Ebit TTM -95.4m / Interest Expense TTM 224k)
EV/FCF = -15.83x (Enterprise Value 1.34b / FCF TTM -84.6m)
FCF Yield = -6.32% (FCF TTM -84.6m / Enterprise Value 1.34b)
FCF Margin = -131.2% (FCF TTM -84.6m / Revenue TTM 64.5m)
Net Margin = -148.1% (Net Income TTM -95.6m / Revenue TTM 64.5m)
Gross Margin = 13.72% ((Revenue TTM 64.5m - Cost of Revenue TTM 55.7m) / Revenue TTM)
Gross Margin QoQ = 1.82% (prev 10.95%)
Tobins Q-Ratio = 4.12 (Enterprise Value 1.34b / Total Assets 325.4m)
Interest Expense / Debt = 0.58% (Interest Expense 224k / Debt 38.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -75.3m (EBIT -95.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.61 (Total Current Assets 258.2m / Total Current Liabilities 39.0m)
Debt / Equity = 0.15 (Debt 38.8m / totalStockholderEquity, last quarter 254.8m)
Debt / EBITDA = 2.27 (negative EBITDA) (Net Debt -194.4m / EBITDA -85.5m)
Debt / FCF = 2.30 (negative FCF - burning cash) (Net Debt -194.4m / FCF TTM -84.6m)
Total Stockholder Equity = 219.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.92% (Net Income -95.6m / Total Assets 325.4m)
RoE = -43.52% (Net Income TTM -95.6m / Total Stockholder Equity 219.5m)
RoCE = -38.06% (EBIT -95.4m / Capital Employed (Equity 219.5m + L.T.Debt 31.0m))
RoIC = -25.90% (negative operating profit) (NOPAT -75.3m / Invested Capital 290.9m)
WACC = 19.40% (E(1.53b)/V(1.57b) * Re(19.88%) + D(38.8m)/V(1.57b) * Rd(0.58%) * (1-Tc(0.21)))
Discount Rate = 19.88% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 39.30%
[DCF] Fair Price = unknown (Cash Flow -84.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.07 | # QB: 0
Revenue Correlation: -5.03 | Revenue CAGR: -0.57% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.26 | Chg30d=+3.79% | Revisions=+12% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.24 | Chg30d=+10.48% | Revisions=+50% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.02 | Chg30d=-0.14% | Revisions=+22% | GrowthEPS=-12.6% | GrowthRev=+13.1%
EPS next Year (2027-12-31): EPS=-0.90 | Chg30d=-0.80% | Revisions=-12% | GrowthEPS=+11.9% | GrowthRev=+41.0%
[Analyst] Revisions Ratio: +23% (up=12, down=7)